Sustained PRC1.1 activity preserves gene repression independently of PRC2.2 and restrains leukemic cell differentiation
Nucleic Acids Research · 08.06.2026 · 54 (11)
DOI: 10.1093/nar/gkag529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 11.06.2026. Verfasst von Fatemeh Mojallali und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZGroningen, The Netherlands. Hauptthemen laut MEDLINE: Cell Differentiation, Gene Expression Regulation, Leukemic, Leukemia, Myeloid, Acute, Polycomb Repressive Complex 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dutch Cancer Foundation, Dutch Cancer Society.
Abstract (Originalsprache)
Loss-of-function mutations in BCOR, a subunit of the non-canonical Polycomb Repressive Complex 1.1 (PRC1.1), are frequently observed in acute myeloid leukemia (AML) and associate with adverse risk. Paradoxically, leukemic stem cell viability in BCOR wild-type AMLs strongly depends on PRC1.1 activity. Here, we use BCOR and KDM2B degron models to study PRC1.1 dependency in leukemic cells and find that BCOR is a bridging factor tethering the catalytic and chromatin-binding moieties of the PRC1.1 complex. BCOR degradation induces a quick localized loss of H2AK119ub at PRC1.1 target genes, whereas PRC2-induced H3K27me3 remains unaffected. Degron-mediated depletion of BCOR or KDM2B induces a rapid but time-dependent transcriptional induction, whereby late-upregulated genes are more heavily decorated with H3K27me3 compared to early-upregulated genes. Combined PRC1.1 inactivation and PRC2 inhibition further amplifies gene induction, suggesting collaborative yet distinct control over target genes. Strikingly, both JARID2/AEBP2 and SUZ12 knockout cells, devoid of PRC2.2 or PRC2.1/PRC2.2 respectively, retain PRC1.1 loss-induced transcriptional activation, underscoring that PRC1.1 can repress target genes independently of a downstream PRC2.2-canonical PRC1 repressive axis. Finally, combined targeting of PRC1.1 and PRC2 induces differentiation of leukemic cells, emphasizing that co-targeting PRC1.1 and PRC2 represents a promising strategy to improve treatment of AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZGroningen, The Netherlands.
- Department of Molecular Biology, Faculty of Science and Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands.
ORCID-Profile: Fatemeh Mojallali, Alessandra De Meis, Sinne G Alkema, Vincent van den Boom
Förderung
- Dutch Cancer Foundation
- Dutch Cancer Society
Zitieren
APA
Mojallali, F., De Meis, A., Alkema, S. G., Atsma, T. J., Hogeling, S. M., Kloosterman, R., Ioannou, E., Wierenga, A. T. J., Huls, G., Martens, J. H. A., Schuringa, J. J., & van den Boom, V. (2026). Sustained PRC1.1 activity preserves gene repression independently of PRC2.2 and restrains leukemic cell differentiation. Nucleic Acids Research, 54(11). https://doi.org/10.1093/nar/gkag529
Vancouver
Mojallali F, De Meis A, Alkema SG, Atsma TJ, Hogeling SM, Kloosterman R, et al. Sustained PRC1.1 activity preserves gene repression independently of PRC2.2 and restrains leukemic cell differentiation. Nucleic Acids Research. 2026;54(11). doi:10.1093/nar/gkag529
BibTeX
@article{Mojallali2026,
author = {Mojallali, Fatemeh and De Meis, Alessandra and Alkema, Sinne G and Atsma, Tjerk Jan and Hogeling, Shanna M and Kloosterman, Rianne and Ioannou, Eve and Wierenga, Albertus T J and Huls, Gerwin and Martens, Joost H A and Schuringa, Jan Jacob and van den Boom, Vincent},
title = {Sustained PRC1.1 activity preserves gene repression independently of PRC2.2 and restrains leukemic cell differentiation},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {11},
doi = {10.1093/nar/gkag529}
}
EUVIMED